메뉴 건너뛰기
Drugs
Volumn 60, Issue 6, 2000, Pages 1371-1379
Lopinavir
Author keywords

[No Author keywords available]
Indexed keywords

ANTIRETROVIRUS AGENT; CHOLESTEROL; EFAVIRENZ; LAMIVUDINE; LIVER ENZYME; LOPINAVIR; NELFINAVIR; NEVIRAPINE; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;
EID: 0034519616     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-200060060-00009     Document Type: Review
Times cited : (107)
References (38)
  • 2
    • 0032566194 scopus 로고    scopus 로고
    • 1998 Revision to the British HIV Association guidelines for antiretroviral treatment of HIV seropositive individuals
    • Jul 25
    • (1998) Lancet , vol.352 , pp. 314-316
    • Gazzard, B.1    Moyle, G.2    Bhiva, G.W.C.3
  • 3
    • 0032562338 scopus 로고    scopus 로고
    • Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents
    • Apr 24
    • (1998) MMWR Morb Mortal Wkly Rep , vol.47 , Issue.SUPPL. RR-5 , pp. 43-83
  • 6
    • 0032566902 scopus 로고    scopus 로고
    • Human serum attenuates the activity of protease inhibitors toward wild-type and mutant human immunodeficiency virus
    • Oct 25
    • (1998) Virology , vol.250 , pp. 255-262
    • Molla, A.1    Vasavanonda, S.2    Kumar, G.3
  • 8
    • 0031849665 scopus 로고    scopus 로고
    • In vitro selection and characterization of human immunodeficiency virus type I variants with increased resistance to ABT-378, a novel protease inhibitor
    • Sep
    • (1998) J Virol , vol.72 , pp. 7532-7541
    • Carrillo, A.1    Stewart, K.D.2    Sham, H.L.3
  • 9
    • 0006616933 scopus 로고    scopus 로고
    • Kaletra (ABT-378/ritonavir) and efavirenz: 48-week safety/efficacy evaluation in multiple PI-experienced patients [poster no. F150]. Poster presentation, 5th International Congress on Drug Therapy in HIV Infection; 2000 Oct 22-26; Glasgow
    • Rockstroh, J.1    Brun, S.2    Bertz, R.3
  • 10
    • 0006595972 scopus 로고    scopus 로고
    • Durable suppression of HIV+ RNA after two years of Kaletra (ABT-378/ritonavir) therapy in single protease inhibitor experienced patients. Poster presentation, 5th International Congress on Drug Therapy in HIV Infection; 2000 Oct 22-26; Glasgow
    • Feinberg, J.1    Brun, S.2    Marsh, T.3
  • 11
    • 0006603328 scopus 로고    scopus 로고
    • Interpretation of phenotypic and genotypic resistance to Kaletra™ (ABT-378/ritonavir) in protease inhibitor experienced patients [poster no. F148-F149]. Poster presentation, 5th International Congress on Drug Therapy in HIV Infection; 2000 Oct 22-26; Glasgow
    • Kempf, D.J.1    Isaacson, J.2    King, M.3
  • 14
    • 0006532239 scopus 로고    scopus 로고
    • Lack of resistance to Kaletra™ (formerly known as ABT-378/r) observed through 24 weeks of therapy in antiretroviral-naïve subjects. Poster presentation, 5th International Congress on Drug Therapy in HIV Infection; 2000 Oct 22-26; Glasgow
    • Bernstein, B.1    Kempf, D.2    Moseley, J.3
  • 16
    • 0006563356 scopus 로고    scopus 로고
    • Baseline genotype and phenotype do not predict response to ABT-378/ritonavir (ABT-378/r) in PI-experienced HIV+ patients at 24 and 48 weeks [poster no. 731]. 7th Conference on Retroviruses and Opportunistic Infections; 2000 Jan 30-Feb 2; San Francisco (CA)
    • Kempf, D.1    Xu, Y.2    Brun, S.3
  • 17
    • 0006532240 scopus 로고    scopus 로고
    • ABT-378/ritonavir (ABT-378/r) suppresses HIV RNA to <400 copies/mL in 86% of PI-experienced HIV+ patients at 48 weeks [poster no. 532]. 7th Conference on Retroviruses and Opportunistic Infections; 2000 Jan 30-Feb 2; San Francisco (CA)
    • Deeks, S.1    Brun, S.2    Xu, Y.3
  • 18
    • 0032811807 scopus 로고    scopus 로고
    • Potent inhibition of the cytochrome P-450 3A-mediated human liver microsomal metabolism of a novel HIV protease inhibitor by ritonavir: A positive drug-drug interaction
    • Aug
    • (1999) Drug Metab Dispos , vol.27 , pp. 902-908
    • Kumar, G.N.1    Dykstra, J.2    Roberts, E.M.3
  • 21
    • 0006557766 scopus 로고    scopus 로고
    • Multiple-dose pharmacokinetics (PK) of ABT-378/ritonavir (ABT/r) in HIV+ subjects [poster no. 0327]. 39th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1999 Sep 26-29; San Francisco (CA)
    • Bertz, R.1    Lam, W.2    Brun, S.3
  • 24
    • 17044457875 scopus 로고    scopus 로고
    • ABT-378/ritonavir plus stavudine and lamivudine for the treatment of antiretroviral-naïve adults with HIV-1 infection: 48-Week results
    • In press
    • (2001) AIDS
    • Murphy, R.L.1    Brun, S.2    Hicks, S.3
  • 25
    • 0006588389 scopus 로고    scopus 로고
    • ABT-378/ritonavir (ABT-378/r) in antiretroviral-naive HIV+ patients: 72 weeks [poster no. 515]. 7th Conference on Retroviruses and Opportunistic Infections; 2000 Jan 30-Feb 2; San Francisco (CA)
    • Gulick, R.1    King, M.2    Brun, S.3
  • 28
    • 0006533372 scopus 로고    scopus 로고
    • Assessment of the pharmacokinetic interaction between Kaletra™ (lopinavir/ritonavir or ABT-378/r) and nevirapine in HIV-infected paediatric subjects [poster no. 440]. Poster presentation, 5th International Congress on Drug Therapy in HIV Infection; 2000 Oct 22-26; Glasgow
    • Hsu, A.1    Bertz, R.2    Renz, C.3
  • 30
    • 0006565916 scopus 로고    scopus 로고
    • Pharmacokinetic interactions between Kaletra™ (lopinavir/ritonavir or ABT-378/r) and other non-HIV drugs [poster 438]. Poster presentation, 5th International Congress on Drug Therapy in HIV Infection; 2000 Oct 22-26; Glasgow
    • Bertz, R.1    Hsu, A.2    Lam, W.3
  • 31
    • 0006588390 scopus 로고    scopus 로고
    • Treatment of HIV+ subjects co-infected with hepatitis B or C safety and efficacy comparison of Kaletra™ (ABT-378/ritonavir) vs. nelfinavir from a phase III blinded randomized clinical trial. Poster presentation, 5th International Congress on Drug Therapy in HIV Infection; 2000 Oct 22-26; Glasgow
    • Arribas, J.1    Barros, C.2    Gonzalez-Lahoz, J.3
  • 32
    • 0006588752 scopus 로고    scopus 로고
    • Kaletra (ABT-378/ritonavir) in antiretroviral-naïve HIV+ patients: Follow up beyond two years and viral load suppression below 3 copies/ml. Poster presentation, 5th International Congress on Drug Therapy in HIV Infection; 2000 Oct 22-26; Glasgow
    • Stryker, R.1    Brun, S.2    King, M.3
  • 36
    • 0006582632 scopus 로고    scopus 로고
    • Kaletra™ (ABT-378/ritonavir) in HIV-infected children at 48 weeks. Poster presentation, 5th International Congress on Drug Therapy in HIV Infection; 2000 Oct 22-26; Glasgow
    • Cahn, P.1    Violari, A.2    Saez-Llorens, X.3

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.